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Edited by Laszlo NagyAbstract The abundance of the adiponectin receptors, AdipoR1
and AdipoR2, and the eﬀects of the antidiabetic adipokine adipo-
nectin in monocytes of normal-weight and overweight controls
and type 2 diabetic patients (T2D) were analyzed. AdipoR1
and AdipoR2 mRNAs were increased in monocytes of obese con-
trols and T2D patients when compared to normal-weight con-
trols, and AdipoR1 mRNA positively correlated to AdipoR2
mRNA, the waist to hip ratio and systemic adiponectin. How-
ever, AdipoR1 and AdipoR2 proteins were lower in monocytes
of T2D compared to normal-weight donors. Induction of IL-6
and IL-8 by adiponectin, an eﬀect involving p38 MAPK, was
also reduced in T2D monocytes.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Adiponectin; Monocyte; Type 2 diabetes; Obesity1. Introduction
Adiponectin is an adipocyte-derived adipokine with antidia-
betic, and antiatherosclerotic properties of which systemic lev-
els are reduced in obesity, type 2 diabetes and coronary artery
disease [1–3]. In vitro studies show that adiponectin induces
the cell death of myelomonocytic progenitor cells, reduces
foam cell formation in macrophages and prevents the adhesion
of monocytes to TNF-activated endothelial cells [4,5]. In addi-
tion, adiponectin inﬂuences the secretion of cytokines and che-
mokines. The LPS-stimulated release of the multifunctional
cytokine IL-6 is reduced in macrophages [6,7], whereas in
non-activated cells an induction of IL-6 has been reported
[6,8]. Furthermore, adiponectin inhibits IL-8 secretion of
human macrophages co-cultivated with apoptotic cells, whereas
the IL-8 production of LPS-activated macrophages was rather
augmented by adiponectin irrespective of the presence or ab-
sence of apoptotic cells [9]. An elevated release of IL-8 by
adiponectin is also found in non-activated macrophages
[8,10] and cytokine-mediated IL-8 release is not inhibited by*Corresponding author. Fax: +49 941 944 7019.
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rather be considered to function as an immunoregulator than
an antiinﬂammatory protein.
Adiponectin activity depends on the adiponectin receptors 1
and 2 and the mRNAs of these receptors are expressed in
monocytes [11,12]. In ob/ob mice, AdipoR1 and AdipoR2
mRNAs are reduced in skeletal muscle and adipose tissue
[13]. In human skeletal muscle of ﬁrst degree relatives of type
2 diabetes patients [14], the mRNA expression of these recep-
tors is also lower. High-fat feeding, however, increases hepatic
AdipoR1 and AdipoR2 mRNA and muscle AdipoR1 in mice
[15].
The insulin/phosphoinositide 3-kinase/Foxo1 pathway regu-
lates AdipoR1 and AdipoR2 mRNA expression and whereas
fasting and insulin deﬁciency elevate the mRNA levels, insulin
replenishment and feeding reduces AdipoR1 and AdipoR2 in
the liver and skeletal muscle of mice [13]. AdipoR1 is involved
in adiponectin-mediated phosphorylation of the AMP kinase
and induction of IL-6 secretion by the p38 MAPK pathway,
whereas AdipoR2 is important for the activation of peroxi-
some proliferator activated receptor-a [11,16].
Most of the data published so far indicate that circulating
adiponectin and the mRNA expression of AdipoR1 and Adi-
poR2 are reduced in insulin resistance postulating a state of
adiponectin resistance in glucose intolerant animals and hu-
mans. Therefore, in the current study AdipoR1 and AdipoR2
mRNA and protein and the response to adiponectin were ana-
lyzed in monocytes of normal-weight controls, overweight pro-
bands and type 2 diabetes patients.2. Materials and methods
2.1. Material
RPMI medium was obtained from Gibco BRL (Karlsruhe, Ger-
many). Recombinant human adiponectin expressed in a mammalian
cell line, DuoSet ELISA Development Systems for human adiponectin,
IL-10, IL-8 and IL-6 were from R&D Systems (Wiesbaden-Nordens-
tadt, Germany), Vacutainer CPT were from Becton Dickinson (Frank-
lin Lakes, NJ). ApoE antibody was from Chemicon (Hampshire, UK)
and CD163 antibody from Serotec (Du¨sseldorf, Germany). The anti-
bodies were used at a 1:1000 dilution for immunoblots. The p38
MAPK inhibitor SB 203580 was from Calbiochem-Merck (Darmstadt,
Germany). The cytotoxicity detection kit was from Roche (Penzberg,
Germany). AdipoR1 antibody was generated as recently described
[17] and AdipoR2 antibody was ordered from EBL (Hamburg, Ger-
many) and used at a dilution of 1:100.blished by Elsevier B.V. All rights reserved.
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The study protocol was approved by the local ethics committee and
the investigation conformed with the principles outlined in the Decla-
ration of Helsinki (1997). Each proband gave written informed consent
to participate in the study.
Monocytes of 11 male T2D patients, 11 male controls with a waist to
hip ratio (WHR) above 1 (CG1) and 11 male controls with a WHR
below 1 (CG2) were isolated. Details of the study groups are given
in Table 1.
T2D patients were treated with metformin, glinides, glitazones, stat-
ins, ﬁbrates, acarbose, aspirin, sulfonylureas and 4 patients were insu-
lin dependent. The probands of the CG1 group were treated with
RAAS inhibitors, aspirin, proton pump inhibitors, doxazosin, or enal-
april and 5 probands had no medication. Probands of the CG2 group
were not on medication.
2.3. Isolation and culture of primary blood monocytes
Peripheral blood leukocytes were isolated from 32 ml of whole blood
by Vacutainer CPT and monocytes were further puriﬁed by magnetic
separation with CD14 beads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Serum was coagulated with Thromborel S (Roche Diag-
nostics GmbH, Mannheim, Germany) and CaCl2 and was 3-times dia-
lyzed against PBS for 2 h. Monocytes (3 · 106) were cultivated in 1 ml
RPMI medium supplemented with 10% autologous serum for 24 h.
Subsequently, the medium was replaced. Monocytes were either culti-
vated in RPMI supplemented with 10% autologous serum or in the
identical medium supplemented with 10 lg/ml adiponectin. Superna-
tants were collected 24 h later and used for ELISA. MAPK inhibitor
was added 1 h before the addition of adiponectin.
2.4. Real-time RT-PCR
Real-time RT-PCR was performed as recently described [17]. The
speciﬁcity of the PCRs was conﬁrmed by sequencing of the PCR frag-
ments. Primers for AdipoR1 and AdipoR2 were used as previously
published [17]. The primers for b-actin were 5 0-CTA CGT CGC
CCT GGA CTT CGA GC-3 0 (b-actin uni), and 5 0-GAT GGA GCC
GCC GAT CCA CAC GG-3 0 (b-actin rev). IL-6 was ampliﬁed with
IL-6 uni (5 0-GCC CAG CTA TGA ACT CCT TCT-3 0) and IL-6 rev
(5 0-GCG GCT ACA TCT TTG GAA TC-3 0) and IL-8 was ampliﬁed
with IL-8 uni (5 0-ACC GGA AGG AAC CAT CTC ACT G-3 0) and
IL-8 rev (5 0-GCA TCT GGC AAC CCT ACA ACA-3 0).
2.5. ELISA
The ELISAs were performed as recommended by the distributor.
Supernatants were used undiluted for IL-10 determination. For IL-8
ELISA supernatants of control-treated monocytes were diluted
1:1000 and of adiponectin incubated cells 1:5000 and 1:10 or 1:100,
respectively, for IL-6 ELISA. EDTA-plasma was diluted 1:5000 to
determine adiponectin. All measurements were performed in duplicate.
2.6. SDS–PAGE and immunoblotting
Monocytes (3 · 106) were washed with PBS and solubilized in
50 ll RIPA buﬀer. Fifteen micrograms of protein was separated
by SDS–polyacrylamide gel electrophoresis and transferred to PVDF
membranes (Bio-Rad, Mu¨nchen, Germany). Incubations with anti-Table 1
Anthropometrical and biochemical characteristics of the study groups (only
T2D CG1
N 11 11
Age (years) 60.5 (42.0–76.0) 57.0 (40.0–7
BMI (kg/m2) 33.0 (27.2–45.9) 30.1 (27.7–3
WHR 1.06 (0.91–1.11) 1.04 (0.99–1
WC (cm) 111 (108–133) 110 (95–118
HDL (mg/dl) 45.0 (35.0–71.0) 42.8 (24.2–6
TG (mg/dl) 149.5 (88.0–737.0) 113.8 (78.8–
Cholesterol (mg/dl) 175.1 (126.0–265.0) 167.4 (115.2
Adiponectin (lg/ml) 1.65 (0.58–3.84) 2.29 (1.00–5
Control group 1 (CG1), control group 2 (CG2), body mass index (BMI), wa
aSigniﬁcance of T2D versus CG2.
bSigniﬁcance of CG1 versus CG2.bodies were performed in 1% BSA in PBS, 0.1% Tween overnight.
Detection of the immune complexes was carried out with the ECL
Western blot detection system (Amersham Pharmacia, Deisenhofen,
Germany).
2.7. Statistics
Data are given as the median values and the range of the values
(SPSS 12.0 for Windows). Data are represented as Box Plots indicating
the median, the upper and lower quartile, the largest and the lowest va-
lue in the data set. Statistical diﬀerences were analyzed by two-tailed
Mann–Whitney U-Test or Wilcoxon Test for paired samples and a va-
lue of P < 0.05 was taken as statistically signiﬁcant. The Pearsons cor-
relation was calculated using the SPSS 12.0 software.3. Results
3.1. AdipoR1 and AdipoR2 mRNA and protein in monocytes of
controls and T2D patients
Monocytes were isolated from normal-weight controls
(CG2), overweight donors (CG1) and T2D patients and the
AdipoR1 and AdipoR2 mRNA levels were analyzed. The
expression of AdipoR1 mRNA normalized to b-actin was
0.63 (0.28–1.23) in CG2, 1.11 (0.75–4.49) in CG1 and 2.47
(0.42–4.70) in T2D monocytes. Monocytes of the CG1 and
of T2D patients expressed similar levels of AdipoR1 mRNA
and signiﬁcantly higher levels compared to CG2 (P = 0.001
for CG1 and T2D, respectively) (Fig. 1A). AdipoR2 mRNA
in CG2 was 0.66 (0.24–1.14) thus being signiﬁcantly higher
in CG1 with 0.96 (0.59–2.14) (P = 0.008) and T2D monocytes
with 0.88 (0.34–2.07) (P = 0.036). Expression of AdipoR2
mRNA was similar in monocytes of T2D patients and CG1
(Fig. 1B). AdipoR1 mRNA positively correlated to the BMI
(r = 0.43, P = 0.012), the waist circumference (r = 0.5,
P = 0.003), and the waist to hip ratio (WHR) (r = 0.53,
P = 0.002) (Fig. 1C), whereas AdipoR2 mRNA did not corre-
late to these anthropometrical factors (not shown). In addi-
tion, there was a positive correlation of the AdipoR1 to the
AdipoR2 mRNA level (r = 0.61, P = 0.0001) when expression
in the monocytes of all probands was considered (Fig. 1D).
AdipoR1 and AdipoR2 protein were analyzed by immunoblot
in monocytes of 6 T2D patients and 6 normal-weight controls
and the results of 3 probands of each group are shown in
Fig. 1E. Quantiﬁcation of the immunoblots and normalization
to b-actin levels revealed that AdipoR1 protein was 9.7 (7.4–
12.0) in CG2 and 7.0 (5.8–7.1) in T2D cells (P = 0.004). Adi-
poR2 was 6.3 (3.2–10.4) in CG2 and 2.9 (0.3–4.0) in T2D
monocytes (P = 0.01).males)
CG2 P-value
11 ns
2.0) 56.0 (44.0–67.0) ns
6.5) 23.6 (20.0–27.7) 0.0001a, 0.0001b
.13) 0.93 (0.83–0.98) 0.0001a, 0.0001b
) 105 (86–113) 0.01b
1.0) 51.7 (39.1–78.0) 0.016b
381.5) 89.5 (49.0–224.0) 0.014a
–228.0) 189.0 (145.8–230.4) ns
.60) 2.22 (1.16–4.18) ns
ist circumference (WC), waist to hip ratio (WHR), triglycerides (TG).
Fig. 1. AdipoR1 and AdipoR2 in monocytes of type 2 diabetes
patients (T2D), overweight controls (CG1) and normal-weight con-
trols (CG2) and correlation to the waist to hip ratio (WHR). (A)
AdipoR1 mRNA was determined by real-time RT-PCR in monocytes
of the three groups mentioned above and the expression was
normalized to b-actin mRNA levels. (B) AdipoR2 mRNA was
determined by real-time RT-PCR in monocytes of the three groups
mentioned above and was normalized to b-actin mRNA levels. (C)
Correlation of monocytic AdipoR1 mRNA to the WHR. (D)
Correlation of monocytic AdipoR1 and AdipoR2 mRNAs. (E)
AdipoR1 and AdipoR2 protein in monocytes of three diﬀerent CG2
(CG1 to CG3) and three diﬀerent T2D (T2D_1 to T2D_3) donors.
*P < 0.05.
Fig. 2. Adiponectin-mediated induction of AdipoR1 and AdipoR2 in
primary monocytes. (A) Monocytes of eight healthy individuals were
incubated with 10 lg/ml adiponectin for 24 h and AdipoR1 and
AdipoR2 mRNA expression normalized to b-actin mRNA is shown.
The circles indicate outliers. (B) Monocytes were cultivated as
described in (A) and AdipoR1 and b-actin were analyzed by
immunoblot. (C) Monocytes were cultivated as described in (A) and
AdipoR2 and b-actin were analyzed by immunoblot. Monocytes of
healthy individuals were incubated with 10 lg/ml adiponectin for 24 h
alone, with 200 nM p38 MAPK inhibitor (I) or adiponectin in
combination with 200 nM p38 MAPK inhibitor and AdipoR1 (D)
and AdipoR2 (E) were determined. *P < 0.05.
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AdipoR1 and AdipoR2 mRNA were measured in mono-
cytes of 8 normal-weight individuals cultivated without or with
10 lg/ml adiponectin for 24 h. AdipoR1 mRNA normalized to
b-actin mRNA was 0.57 (0.28–0.87) in control-incubated cells
and was induced to 1.05 (0.75–1.45) by adiponectin
(P = 0.001). AdipoR2 mRNA was 0.65 (0.24–0.83) in the con-
trol cells and was also signiﬁcantly (P = 0.007) upregulated to
0.96 (0.25–1.26) by adiponectin (Fig. 2A). However, there was
only a weak positive correlation of AdipoR1 (r = 0.41,
P = 0.018) and no correlation of AdipoR2 mRNA (r = 0.34,
P = 0.05) with systemic adiponectin levels (not shown). Immu-
noblot was performed with monocytes isolated of three diﬀer-
ent normal-weight donors that were incubated with 10 lg/ml
adiponectin for 24 h and the result of a representative experi-
ment is shown in Fig. 2B and C. AdipoR1 protein and Adi-
poR2 protein were detected in the monocytes by
immunoblot and were slightly upregulated (1.5-fold (1.3–1.7)for AdipoR1 and 2.1-fold (1.8–2.7) for AdipoR2) by adiponec-
tin in vitro. However, an induction of the receptors was not
observed when monocytes of 5 T2D patients were analyzed
(not shown).
Adiponectin activates the p38 MAPK and therefore the ef-
fect of adiponectin on AdipoR1 and AdipoR2 induction was
determined in monocytes pretreated with the p38 MAPK
inhibitor SB 203580 at a concentration of 200 nM. Upregula-
tion of the receptors was not inﬂuenced by this inhibitor
(Fig. 2D and E).
3.3. Adiponectin upregulates IL-6 and IL-8 via the p38 MAPK
pathway
We and others have recently demonstrated that adiponectin
enhances IL-6 and IL-8 release in monocytes [6,9,10]. How-
ever, it has not been analyzed whether the mRNA expression
of these proteins is induced. Abundance of IL-6 mRNA in
monocytes of the 8 normal-weight individuals was 0.40
(0.07–2.55) and was upregulated by adiponectin to 22.6 (3.3–
49.2) (P = 0.03). IL-8 mRNA in the monocytes was 0.37
(0.05–1.23) and was increased by adiponectin to 9.51 (1.91–
45.4) (P = 0.02) indicating that the transcription or the mRNA
stability is enhanced by adiponectin (not shown).
Because p38 MAPK may be involved in the induction of
these proteins, monocytes of three healthy controls (three inde-
pendent experiments per donor) were incubated with 10 lg/ml
adiponectin alone or in combination with the p38 MAPK
inhibitor SB 203580 at a concentration of 100 nM or
200 nM. IL-6 secretion from control-incubated cells was
256.0 (162.1–265.0) pg/ml and 100 nM or 200 nM inhibitor
1780 J. Weigert et al. / FEBS Letters 582 (2008) 1777–1782did not signiﬁcantly inﬂuence IL-6 release. Adiponectin upreg-
ulated IL-6 to 1984 (1897–2075) pg/ml (P = 0.001 versus con-
trol). 100 nM of the inhibitor reduced adiponectin-stimulated
IL-6 release to 1122 (523–1420) pg/ml (P = 0.007 versus adipo-
nectin stimulated cells) and 200 nM of the inhibitor lowered
secretion of IL-6 to 821 (272–892) pg/ml (P < 0.001 versus
adiponectin-stimulation) (Fig. 3A). Basal IL-8 release was
30.1 (22.7–34.8) ng/ml and in adiponectin treated monocytes
88.7 (84.4–98.1) ng/ml (P < 0.001 when compared to mono-
cytes not incubated with adiponectin). 100 nM SB 203580
did not alter IL-8 whereas 200 nM of the inhibitor lowered ba-
sal IL-8 to 21.6 (18.7–24.6) ng/ml (P = 0.002 versus control).
Adiponectin induced IL-8 was reduced by 100 nM of SB
203580 to 69.1 (56.2–78.8) ng/ml and by 200 nM SB 203580
to 60.4 (48.9–79.5) ng/ml (P < 0.001 versus adiponectin-treated
cells for both concentrations) (Fig. 3B) indicating that p38
MAPK signaling is important for IL-6 and IL-8 induction
by adiponectin.Fig. 3. Adiponectin-mediated induction of IL-6 and IL-8 depends on
the p38 MAPK and is reduced in monocytes of type 2 diabetes
patients. (A) Monocytes of three healthy individuals were incubated
with 10 lg/ml adiponectin, with 100 nM or 200 nM p38 MAPK
inhibitor, or with adiponectin in combination with 100 nM or 200 nM
p38 MAPK inhibitor and IL-6 (A), IL-8 (B), IL-10 (C), soluble (s)
CD163 and ApoE (D) were determined in the supernatants. (E)
Monocytes of type 2 diabetes patients (T2D), overweight controls
(CG1) and normal-weight controls (CG2) were incubated with
medium alone, or medium and 10 lg/ml adiponectin for 24 h and
adiponectin-induced IL-6 relative to control-cultivated monocytes is
given. The circles indicate outliers. (F) Monocytes of type 2 diabetes
patients (T2D), overweight controls (CG1) and normal-weight con-
trols (CG2) were incubated with medium alone or medium and 10 lg/
ml adiponectin for 24 h and adiponectin-induced IL-8 relative to
control-cultivated monocytes is given. The circles indicate outliers.
*P < 0.05, non signiﬁcant (ns).To ﬁnd out whether the inhibitory eﬀects of the inhibitor
were speciﬁc the release of IL-10, apolipoprotein E (Apo E)
and soluble CD163 were determined in these supernatants.
IL-10 is upregulated by adiponectin [18,19] and was also
slightly induced in the monocytes studied herein. IL-10 in
the supernatant of adiponectin-treated cells was 128.3%
(117.0–130, P = 0.01 versus control) when controls were set
to 100%. However, this induction was not reduced by the
p38 MAPK inhibitor (Fig. 3C). Secretion of ApoE, a protein
that is repressed in lipopolysaccharide stimulated macrophages
[20] and soluble CD163, a macrophage speciﬁc receptor that is
shedded from the cells in response to pathogen infections [21],
were similar in all supernatants (Fig. 3D). In addition, the re-
lease of lactat dehydrogenase as a marker of cell death was
determined and was similar in all supernatants (not shown).
3.4. Adiponectin resistance in monocytes of T2D patients
The adiponectin stimulated release of IL-6 and IL-8 was also
determined in the monocytes of CG2, CG1 and T2D and the
ratio of IL-6 release in adiponectin-treated cells to IL-6 secre-
tion of cells cultivated in medium alone was calculated for
monocytes of each donor separately. IL-6 induction was high-
est in CG2 monocytes (36.8-fold induction, range 7.7–485),
tended to be lower in CG1 cells (4.1-fold, range 1.4–129.0)
and was signiﬁcantly lower in monocytes of T2D patients with
a 4.4-fold upregulation (range 1.4–54.0, P = 0.008) when com-
pared to CG2 (Fig. 3E). IL-8 upregulation was 6.8-fold (1.4–
108) in CG2, 3.6-fold (1.6–21.5) in CG1 and 1.9-fold (1.5–
8.0) in T2D. Whereas the diﬀerence was not signiﬁcant be-
tween T2D and CG1, adiponectin-mediated increase of IL-8
was reduced in monocytes of T2D (P = 0.004) when compared
to CG2 (Fig. 3F).4. Discussion
Recent investigations in knock-out mice revealed that the
biologic activity of adiponectin depends on the adiponectin
receptors AdipoR1 and AdipoR2 [11]. Whereas several studies
demonstrated that systemic adiponectin is reduced in obesity,
type 2 diabetes or patients with coronary artery disease, the
levels of the corresponding receptors have not been extensively
studied [2,3,22]. A lower expression of AdipoR1 and AdipoR2
mRNA was described in human skeletal muscle of ﬁrst degree
relatives of type 2 diabetes patients [13,14], whereas a second
study found a positive correlation of AdipoR1 mRNA expres-
sion in human myotubes with insulin, C-peptide, plasma tri-
glycerides and cholesterol [23]. The expression of AdipoR2
mRNA was only associated with plasma triglyceride concen-
trations [23].
In the current experiments, an elevated mRNA expression of
AdipoR1 and AdipoR2 was demonstrated in monocytes of
overweight probands and type 2 diabetes patients. Oral medi-
cation like PPARa and PPARc agonists, that inﬂuence adipo-
nectin receptor 2 mRNA [12] most likely do not explain
elevated expression of both receptors because, at least in the
obese controls, these drugs have not been applied. The mRNA
levels of AdipoR1 and AdipoR2 showed a strong positive cor-
relation indicating a co-regulation of the receptors. AdipoR1
and AdipoR2 protein, however, were found reduced in mono-
cytes of T2D when compared to normal-weight controls.
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duced protein abundance although this has to be veriﬁed in a
larger study cohort.
In vitro, adiponectin induced AdipoR1 and AdipoR2
mRNA and protein in monocytes of normal-weight controls
but not of T2D patients. Systemic adiponectin did not corre-
late with monocytic AdipoR2 mRNA and there was only a
weak positive correlation with monocytic AdipoR1 mRNA
indicating that circulating adiponectin may not represent a
major regulator of monocytic adiponectin receptor mRNA
levels in vivo. AdipoR1 mRNA positively correlated to the
WHR, and therefore, soluble factors inﬂuenced by obesity
and/or visceral fat mass, besides adiponectin, may modulate
monocytic expression of AdipoR1.
Adiponectin receptor mRNA and protein have not been
compared in circulating monocytes of probands with impaired
and normal glucose tolerance so far. Alberti et al. determined
the mRNAs of these receptors in lymphocytes of obese individ-
uals and the abundance of AdipoR1 and AdipoR2 in lympho-
cytes of normal glucose tolerant donors tended to be reduced
when compared to lymphocytes of impaired glucose tolerant
donors or T2D patients [24]. In addition, similar to our data,
a positive correlation of AdipoR1 mRNA with systemic adipo-
nectin was identiﬁed [24]. Several studies have demonstrated
that adiponectin reduces the release of proinﬂammatory cyto-
kines in LPS-activated monocytes, and thus, it was initially de-
scribed as an antiinﬂammatory molecule [7,25]. In contrast,
adiponectin also induced IL-6, IL-8 and MCP-1 in non-acti-
vated monocytes, and therefore, is more properly regarded as
an immuno-modulatory factor [8–10]. In the current experi-
ments, we demonstrated that the enhanced secretion of IL-6
and IL-8 in adiponectin treated monocytes was associated with
elevated IL-6 and IL-8 mRNA levels. Inhibition of the p38
MAPK abrogated adiponectin-mediated release of IL-6 and
IL-8 indicating that adiponectin activates the p38 MAPK sig-
naling pathway in monocytes. Adiponectin-mediated induction
of IL-6 and IL-8 was reduced in monocytes of T2D patients and
tended to be lower in monocytes of the obese donors. Therefore
the inﬂuence of adiponectin is impaired in monocytes of T2D
patients and this may be explained by the reduced abundance
of AdipoR1 protein that was demonstrated to mediate adipo-
nectin-stimulated activation of the p38 MAPK and subsequent
IL-6 release at least in ﬁbroblasts [16].
To summarize, the current experiments indicate that mono-
cytes of type 2 diabetes patients have reduced AdipoR1 and
AdipoR2 protein and this may explain the impaired response
to adiponectin-mediated activation of the p38 MAPK signal-
ling pathway.
Acknowledgements: The technical assistance of Natalie Smolnikow and
Kerstin Winkler is greatly appreciated. The study was supported by
grants from the Deutsche Diabetes-Stiftung.References
[1] Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K.,
Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T.,
Miyaoka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo,
K., Matsubara, K., Muraguchi, M., Ohmoto, Y., Funahashi, T.
and Matsuzawa, Y. (1999) Paradoxical decrease of an adipose-
speciﬁc protein, adiponectin, in obesity. Biochem. Biophys. Res.
Commun. 257, 79–83.
[2] Shimada, K., Miyazaki, T. and Daida, H. (2004) Adiponectin and
atherosclerotic disease. Clin. Chim. Acta 344, 1–12.[3] Lara-Castro, C., Fu, Y., Chung, B.H. and Garvey, W.T. (2007)
Adiponectin and the metabolic syndrome: mechanisms mediating
risk for metabolic and cardiovascular disease. Curr. Opin.
Lipidol. 18, 263–270.
[4] Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama,
A., Ouchi, N., Kihara, S., Funahashi, T., Tenner, A.J., Tomiy-
ama, Y. and Matsuzawa, Y. (2000) Adiponectin, a new member
of the family of soluble defense collagens, negatively regulates the
growth of myelomonocytic progenitors and the functions of
macrophages. Blood 96, 1723–1732.
[5] Ouchi, N., Kihara, S., Arita, Y., Nishida, M., Matsuyama, A.,
Okamoto, Y., Ishigami, M., Kuriyama, H., Kishida, K., Nishiz-
awa, H., Hotta, K., Muraguchi, M., Ohmoto, Y., Yamashita, S.,
Funahashi, T. and Matsuzawa, Y. (2001) Adipocyte-derived
plasma protein, adiponectin, suppresses lipid accumulation and
class A scavenger receptor expression in human monocyte-derived
macrophages. Circulation 103, 1057–1063.
[6] Neumeier, M., Weigert, J., Schaﬄer, A., Wehrwein, G., Muller-
Ladner, U., Scholmerich, J., Wrede, C. and Buechler, C. (2006)
Diﬀerent eﬀects of adiponectin isoforms in human monocytic
cells. J. Leukoc. Biol. 79, 803–808.
[7] Wulster-Radcliﬀe, M.C., Ajuwon, K.M., Wang, J., Christian, J.A.
and Spurlock, M.E. (2004) Adiponectin diﬀerentially regulates
cytokines in porcine macrophages. Biochem. Biophys. Res.
Commun. 316, 924–929.
[8] Abke, S., Neumeier, M., Weigert, J., Wehrwein, G., Eggenhofer,
E., Schaﬄer, A., Maier, K., Aslanidis, C., Scholmerich, J. and
Buechler, C. (2006) Adiponectin-induced secretion of interleukin-
6 (IL-6), monocyte chemotactic protein-1 (MCP-1, CCL2) and
interleukin-8 (IL-8, CXCL8) is impaired in monocytes from
patients with type I diabetes. Cardiovasc. Diabetol. 5, 17.
[9] Saijo, S., Nagata, K., Nakano, Y., Tobe, T. and Kobayashi, Y.
(2005) Inhibition by adiponectin of IL-8 production by human
macrophages upon coculturing with late apoptotic cells. Biochem.
Biophys. Res. Commun. 334, 1180–1183.
[10] Rovin, B.H. and Song, H. (2006) Chemokine induction by the
adipocyte-derived cytokine adiponectin. Clin Immunol 120, 99–
105.
[11] Yamauchi, T. et al. (2007) Targeted disruption of AdipoR1 and
AdipoR2 causes abrogation of adiponectin binding and metabolic
actions. Nat. Med. 13, 332–339.
[12] Chinetti, G., Zawadski, C., Fruchart, J.C. and Staels, B. (2004)
Expression of adiponectin receptors in human macrophages and
regulation by agonists of the nuclear receptors PPARalpha,
PPARgamma, and LXR. Biochem. Biophys. Res. Commun. 314,
151–158.
[13] Tsuchida, A. et al. (2004) Insulin/Foxo1 pathway regulates
expression levels of adiponectin receptors and adiponectin sensi-
tivity. J. Biol. Chem. 279, 30817–30822.
[14] Civitarese, A.E., Jenkinson, C.P., Richardson, D., Bajaj, M.,
Cusi, K., Kashyap, S., Berria, R., Belfort, R., DeFronzo, R.A.,
Mandarino, L.J. and Ravussin, E. (2004) Adiponectin receptors
gene expression and insulin sensitivity in non-diabetic Mexican
Americans with or without a family history of Type 2 diabetes.
Diabetologia 47, 816–820.
[15] Bullen Jr., J.W., Bluher, S., Kelesidis, T. and Mantzoros, C.S.
(2007) Regulation of adiponectin and its receptors in response to
development of diet-induced obesity in mice. Am. J. Physiol.
Endocrinol. Metab. 292, E1079–E1086.
[16] Tang, C.H., Chiu, Y.C., Tan, T.W., Yang, R.S. and Fu, W.M.
(2007) Adiponectin enhances IL-6 production in human synovial
ﬁbroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa
B pathway. J. Immunol. 179, 5483–5492.
[17] Neumeier, M., Weigert, J., Schaﬄer, A., Weiss, T., Kirchner, S.,
Laberer, S., Scholmerich, J. and Buechler, C. (2005) Regulation of
adiponectin receptor 1 in human hepatocytes by agonists of
nuclear receptors. Biochem. Biophys. Res. Commun. 334, 924–
929.
[18] Wolf, A.M., Wolf, D., Rumpold, H., Enrich, B. and Tilg, H.
(2004) Adiponectin induces the anti-inﬂammatory cytokines IL-
10 and IL-1RA in human leukocytes. Biochem. Biophys. Res.
Commun. 323, 630–635.
[19] Kumada, M., Kihara, S., Ouchi, N., Kobayashi, H., Okamoto,
Y., Ohashi, K., Maeda, K., Nagaretani, H., Kishida, K., Maeda,
N., Nagasawa, A., Funahashi, T. and Matsuzawa, Y. (2004)
1782 J. Weigert et al. / FEBS Letters 582 (2008) 1777–1782Adiponectin speciﬁcally increased tissue inhibitor of metallopro-
teinase-1 through interleukin-10 expression in human macro-
phages. Circulation 109, 2046–2049.
[20] Gafencu, A.V., Robciuc, M.R., Fuior, E., Zannis, V.I., Kardassis,
D. and Simionescu, M. (2007) Inﬂammatory signaling pathways
regulating ApoE gene expression in macrophages. J. Biol. Chem.
282, 21776–21785.
[21] Weaver, L.K., Pioli, P.A., Wardwell, K., Vogel, S.N. and Guyre,
P.M. (2007) Up-regulation of human monocyte CD163 upon
activation of cell-surface Toll-like receptors. J. Leukoc. Biol. 81,
663–671.
[22] Goldstein, B.J. and Scalia, R. (2004) Adiponectin: a novel
adipokine linking adipocytes and vascular function. J. Clin.
Endocrinol. Metab. 89, 2563–2568.[23] Staiger, H., Kaltenbach, S., Staiger, K., Stefan, N., Fritsche, A.,
Guirguis, A., Peterﬁ, C., Weisser, M., Machicao, F., Stumvoll, M.
and Haring, H.U. (2004) Expression of adiponectin receptor
mRNA in human skeletal muscle cells is related to in vivo
parameters of glucose and lipid metabolism. Diabetes 53, 2195–
2201.
[24] Alberti, L., Gilardini, L., Girola, A., Moro, M., Cavagnini, F.
and Invitti, C. (2007) Adiponectin receptors gene expression in
lymphocytes of obese and anorexic patients. Diabetes Obes.
Metab. 9, 344–349.
[25] Yamaguchi, N., Argueta, J.G., Masuhiro, Y., Kagishita, M.,
Nonaka, K., Saito, T., Hanazawa, S. and Yamashita, Y. (2005)
Adiponectin inhibits Toll-like receptor family-induced signaling.
FEBS Lett. 579, 6821–6826.
